Drugging RNA with pills: small molecules for a big frontier
Bio Pharma Dive
SEPTEMBER 6, 2022
A handful of startups have formed in recent years with plans to target RNA with small molecules. Many have caught the attention of big drugmakers
RNA Related Topics 
291 
Next-generation RNA technologies: making longer-lasting drugs with a broader reach
Bio Pharma Dive
AUGUST 23, 2022
At least 10 biotechnology startups are trying to use RNA molecules in new ways to make medicines. Here’s a look at where they stand
Join 15,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
China-based biotech licenses Sanofi's RNA drug technology
Bio Pharma Dive
JULY 25, 2022
The Lilly-backed Rona Therapeutics gains rights to a platform for small interfering RNA, along with a slate of preclinical candidates aimed at targets in the liver and other tissues
Amgen partners with Arrakis to develop drugs aimed at RNA
Bio Pharma Dive
JANUARY 11, 2022
Arrakis, a specialist in designing oral drugs that target RNA, will receive $75 million under the deal, which could be worth "several billion dollars" more
2nd Next Generation RNA Therapeutics Summit
Pharma Phorum
JANUARY 13, 2023
Bringing Next Generation RNA Therapies to Patients Faster. The post 2nd Next Generation RNA Therapeutics Summit appeared first on. Events Oncology Immunotherapies rna RNA conference tRNAs vaccine
Ascidian starts up with $50M and a twist on RNA editing
Bio Pharma Dive
OCTOBER 12, 2022
The startup, run by Translate Bio cofounder Romesh Subramanian, believes its RNA “exon editing” approach could have long-lasting effects without the risks that come with editing DNA
Moderna founder unveils new drug company focused on a different kind of RNA
Bio Pharma Dive
NOVEMBER 9, 2021
The biotech is researching how to make medicines from transfer RNA molecules Encouraged by Moderna's success, Flagship Pioneering has been busy creating startups like Alltrna, which launched Tuesday.
Merck makes circular RNA play with $3.5bn Orna alliance
Pharma Phorum
AUGUST 16, 2022
Merck & Co has ramped up its involvement in the RNA category, partnering with US biotech Orna Therapeutics in a deal valued at up to $3.5 Now, Merck has made its own play, partnering with Orna on its proprietary ‘oRNA’ technology, which stands for circular RNA.
Beam-linked startup launches with an eye on the next generation of RNA drugs
Bio Pharma Dive
SEPTEMBER 7, 2022
“We see a huge opportunity in the setting of RNA-based therapies to overcome some of the shortcomings that have been there with the first generation of RNA companies,” said former Alnylam CEO and Orbital Therapeutics co-founder John Maraganore
The Decade of RNA Delivery – Beyond the Liver
BioSpace
MARCH 8, 2023
The Decade of RNA Delivery – Beyond the Liver 3/8/2023
AstraZeneca gives up on Ionis’ RNA drug for heart disease
Bio Pharma Dive
SEPTEMBER 23, 2022
The British drugmaker decided the medicine, which works similarly to Novartis’s Leqvio, wasn’t potent enough to justify further testing
J&J to explore RNA reprogramming with Remix research deal
Bio Pharma Dive
FEBRUARY 17, 2022
The agreement with the Cambridge-based startup is the latest to reflect growing large pharma company interest in targeting RNA with small molecules
As Arrowhead falters, lungs remain a tough target for RNA drugs
Bio Pharma Dive
JULY 6, 2021
The biotech's decision to pause testing of a cystic fibrosis drug is the latest reminder of the difficulty of delivering RNA medicines into the lungs
Beyond Covid-19: the disruptive potential of RNA-based therapeutics
Pharmaceutical Technology
MARCH 1, 2023
Further, the acceptance of new mRNA vaccines has rejuvenated activity within previously established categories of RNA therapeutics including lifesaving antisense technologies. These include antisense oligonucleotides (ASO), RNA interference (RNAi), and RNA aptamers.
14th Annual RNA Therapeutics Conference
Pharma Phorum
NOVEMBER 1, 2022
14th Annual RNA Therapeutics. Investigating the next generation of genetic medicine through RNA based therapies. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 Who should attend: Directors of novel RNA therapies.
Venture capital pours more money into RNA medicines with the launch of Replicate
Bio Pharma Dive
SEPTEMBER 8, 2021
The company, which focuses on self-replicating RNA, comes equipped with $40 million from Apple Tree Partners and a stamp of approval from the former research head at Biogen
Moderna founder's next big play in RNA raises $440 million
Bio Pharma Dive
AUGUST 30, 2021
Just a few months out of stealth mode, Laronde and its "endless RNA" technology have caught the attention of well-known investors like Fidelity, T. Rowe Price Associates and Invus
RNA Therapeutics 2022
Pharma Phorum
OCTOBER 18, 2021
SMi Group’s 13th Annual Conference: RNA Therapeutics 2022. Bolstering the latest advances and opportunities in RNA-based medicine. Delve into the latest innovations in novel RNA delivery and target specificity. Head of RNA Biology.
Next Generation RNA Therapeutics Summit
Pharma Phorum
APRIL 25, 2022
Are you looking to solve challenges with current RNA therapeutics, such as the degradation of RNA by RNAses, the difficulty of RNA crossing the cell membrane by diffusion and the immunogenicity elicited by exogenous RNA? Next generation RNA therapeutics can help!
Eli Lilly Expands RNA Editing Collaboration with ProQR Therapeutics
BioSpace
DECEMBER 21, 2022
Eli Lilly and ProQR Therapeutics expand their RNA-editing collaboration
Gatehouse Bio and AstraZeneca to develop RNA therapeutics for heart failure
Pharmaceutical Technology
SEPTEMBER 9, 2022
US-based biotech company Gatehouse Bio is extending its collaboration with AstraZeneca for developing RNA therapeutics to treat heart failure with preserved ejection fraction (HFpEF). Gatehouse Bio is engaged in developing small RNA-based therapeutics using AI technology.
BioTuring enters collaboration to enable detailed single-cell RNA research
Pharma Phorum
JANUARY 19, 2022
The collaboration aims to “close the gap between single-cell RNA sequencing wet-lab services and single-cell data analysis solutions,” which will allow scientists to study the finest details that can be hard to access. News R&D pharma rna rna therapeutics Single Cell Analysis
Roche adds to RNA drug deal streak with Ribometrix partnership
Bio Pharma Dive
JANUARY 6, 2021
The companies' pact is the latest addition to a growing list of deals involving startups developing chemical drugs to target RNA molecules
Eli Lilly Pursues RNA Editing in New Partnership with ProQR
XTalks
SEPTEMBER 13, 2021
billion deal will see the companies use ProQR’s proprietary Axiomer RNA editing platform technology to advance editing oligonucleotide-based therapeutics toward clinical development and commercialization.
Lilly joins RNA editing race with ProQR deal
Bio Pharma Dive
SEPTEMBER 9, 2021
An agreement with the Dutch biotech, which could be worth as much as $1.3 billion, expands Lilly's work in genetic medicine research
Hallmark cancer gene regulates RNA ‘dark matter’
Scienmag
JULY 19, 2022
A key genetic mutation that occurs early on in cancer alters RNA “dark matter” and causes the release of previously unknown RNA biomarkers for cancer early detection, a new study by UC Santa Cruz researchers published in the journal Cell Reports shows. Cancer cancer dark gene Hallmark matter regulates RNA
Merck pays startup Orna $150M as ‘circular RNA’ attracts industry interest
Bio Pharma Dive
AUGUST 16, 2022
The pharmaceutical company has formed an alliance with Orna and invested $100 million in its Series B round, hoping the young biotech’s approach could lead to multiple new vaccines and drugs
Lilly pays $75M to widen RNA editing deal with ProQR
Bio Pharma Dive
DECEMBER 22, 2022
The expanded deal triples the amount of money the biotech could eventually receive from Lilly and adds several more neurological disease drug targets
Messenger RNA technology shows promise for developing infectious disease therapeutics
Scienmag
JULY 6, 2022
Army scientists and industry partners were among the first to demonstrate that messenger RNA (mRNA)—the technology recently used in COVID-19 vaccines and others—could also be used to develop treatments for infectious diseases.
Double-stranded RNA induces bone loss during gum disease
Scienmag
APRIL 8, 2022
They found that double stranded RNA molecules can activate the immune system response that leads to deterioration of bone. Medicine & Health bone Disease Doublestranded gum induces loss RNA
Biogen taps Envisagenics’ AI to speed up RNA splicing R&D
Pharma Phorum
MAY 14, 2021
Biogen has made a further push into RNA-based drug discovery via a collaboration with Envisagenics, which applies artificial intelligence RNA sequencing data to discover new drug targets and therapeutics. Cambridge, Massachusetts-based Envisagenics focuses on using AI to analyse errors in RNA splicing, a process in which a precursor form of messenger RNA (mRNA) – which is used as a template for protein synthesis in cells – is transformed into a mature form.
Lilly buys into MiNA’s protein-boosting RNA tech in $1.25bn deal
Pharma Phorum
MAY 12, 2021
UK biotech MiNA Therapeutics has signed up another big pharma partner for its small activating RNA (saRNA) platform, which upregulates the activity of proteins, with Eli Lilly the latest to get in on the action. . News R&D Eli Lilly MiNA Therapeutics partnering rna RNA-based drugs
2nd RNA Editing Summit 2020
Pharma Phorum
OCTOBER 5, 2020
The only industry-led meeting showcasing the recent development of RNA editing mechanisms and dedicated to realizing the research and therapeutics opportunity of RNA editing as quickly as possible. The post 2nd RNA Editing Summit 2020 appeared first on.
How RNA-Based Pesticides Can Improve Pest Control
XTalks
NOVEMBER 9, 2021
Perhaps popularized by the COVID-19 vaccines, RNA-based technologies now have the potential to become the next best pesticide to combat crop pests, like insects and fungal pathogens. What are RNA-Based Pesticides? Advantages of RNA-Based Pesticides.
UTSW study: RNA exosome key for B cell development
Scienmag
JUNE 13, 2022
New research from UT Southwestern suggests that RNA exosomes – the cellular machines that degrade old molecules of RNA – play a key role in the development of B cells, which are critical to the immune system’s ability to protect against infection.
RNA Therapeutics Experience Renaissance Amidst Global Pandemic
BioSpace
AUGUST 4, 2021
RNA caught the public’s imagination in the form of mRNA vaccines against COVID-19, but RNA can be used in other ways, too, to make therapeutic proteins
Benchling launches purpose-built tools to accelerate RNA R&D
BioPharma Reporter
SEPTEMBER 7, 2022
Technology firm, Benchling, has developed what it calls the biopharma industryâs first set of full capabilities for designing, modelling, and studying both natural and chemically modified RNA in a single platform.
Switch Therapeutics launches with $52M to capitalize on RNA medicine ‘era’
Bio Pharma Dive
MARCH 14, 2023
The company’s name comes from its goal of developing drugs that only “switch” on in target cells, potentially enabling more precise therapies
???????Research sheds light on mysterious messenger RNA modifications
Scienmag
MARCH 9, 2022
A team led by scientists at the University of Birmingham has come a step closer to uncovering the purpose of a distinctive set of modifications found at the beginning of messenger RNA which have long remained a fundamental mystery in molecular biology.
CAMP4’s funding influx paves the way for tapping regulatory RNA to treat urea cycle disorders
Pharmaceutical Technology
JULY 29, 2022
Last week, CAMP4 Therapeutics announced the close of a $100 million Series B round , which will be used to advance their regulatory RNA (regRNA)-focused programs. In order to find the specific RNA sequences for a genetic disease, the biotech is using an AI- and machine learning-based approach.
Lucerna is Illuminating the Mysteries of RNA to Solve Disease
BioSpace
SEPTEMBER 9, 2021
The company aims to make RNA molecules visible and druggable – opening the door to study RNA-based diseases
Single cell RNA sequencing uncovers new mechanisms of heart disease
Scienmag
MAY 10, 2022
Biology cell Disease heart mechanisms RNA sequencing single uncoversHypertrophic cardiomyopathy is a heart disease that leads to a stressed, swollen heart muscle. Due to a poor understanding of underlying mechanisms, effective clinical treatments are not available.
GSK dives into NASH, RNA interference with Arrowhead deal
Bio Pharma Dive
NOVEMBER 23, 2021
GSK has secured rights to a genetic medicine in early-stage human testing for NASH, a disease thought to affect millions of people and which has proven to be a tough target for drugmakers
Let's personalize your content